/

Workspace

Research & Review

Writing & Publishing

Data & Analysis

Utilities

Account

User Settings

J

Janusz Jaworski

NZOZ Centrum Alergologii(PL)

Claim or correct this author profile

Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.

115

Papers

1.6K

Citations

18

h-index

28

i10-index

Janusz Jaworski is an academic researcher from NZOZ Centrum Alergologii. The author has contributed to research in topics: Biosimilars and Bioanalytical Methods & Sports Performance and Training & Rheumatoid Arthritis Research and Therapies. The author has an h-index of 18, co-authored 98 publications.

ORCID: 0000-0002-2664-1012

Research Topics

Biosimilars and Bioanalytical Methods Sports Performance and Training Rheumatoid Arthritis Research and Therapies Physical Education and Training Studies Pharmaceutical studies and practices

Papers by this author

works

Apremilast, an oral phosphodiesterase 4 inhibitor, in patients with psoriatic arthritis and current skin involvement: a phase III, randomised, controlled trial (PALACE 3)

2016 · Annals of the Rheumatic Diseases · 275 citations

https://doi.org/10.1136/annrheumdis-2015-207963

Christopher J Edwards Francisco J. Blanco Jeffrey Crowley C. Birbara

Efficacy, pharmacokinetics and safety of subcutaneous versus intravenous CT-P13 in rheumatoid arthritis: a randomized phase I/III trial

2020 · Lara D. Veeken · 54 citations

https://doi.org/10.1093/rheumatology/keaa580

René Westhovens Piotr Wiland Marek Zawadzki Delina Ivanova

Efficacy and safety of biosimilar CT-P17 versus reference adalimumab in subjects with rheumatoid arthritis: 24-week results from a randomized study

2021 · Arthritis Research & Therapy · 30 citations

https://doi.org/10.1186/s13075-020-02394-7

Jonathan Kay Janusz Jaworski Rafał Wojciechowski Piotr Wiland

OP0036 EFFICACY, SAFETY, AND PHARMACOKINETICS OF ANTI-CD40 ANTIBODY ABIPRUBART (KPL-404) IN PATIENTS WITH RHEUMATOID ARTHRITIS: A PHASE 2, RANDOMIZED, PLACEBO-CONTROLLED 12-WEEK-TREATMENT PROOF-OF-CONCEPT STUDY

2024 · Annals of the Rheumatic Diseases · 6 citations

https://doi.org/10.1136/annrheumdis-2024-eular.1536

Elizabeth A. Jenkins Ingrid Louw Attila Balog E. Van Duuren

Usability, efficacy, and safety of candidate tocilizumab biosimilar CT-P47 self-administration via auto-injector and pre-filled syringe in patients with rheumatoid arthritis: a single-arm, open-label, phase 3 study

2025 · Expert Review of Clinical Immunology · 4 citations

https://doi.org/10.1080/1744666x.2025.2451215

Gerd R Burmester Piotr Adrian Klimiuk Jakub Trefler Janusz Jaworski

Repeated Switching Between CT-P17 and EU Reference Adalimumab in Patients with Moderate-to-Severe Chronic Plaque Psoriasis: A Randomized, Double-Blind, Active-Controlled, Phase 3, Interchangeability Study

2025 · Advances in Therapy · 3 citations

https://doi.org/10.1007/s12325-024-03100-8

Mark Lebwohl John Koo Janusz Jaworski Jakub Trefler

Research topics

topics

Biosimilars and Bioanalytical Methods

Sports Performance and Training

Rheumatoid Arthritis Research and Therapies

Physical Education and Training Studies

Pharmaceutical studies and practices

Chat about Author

Papers

Chat

Click to start Chat